Overall Survival Clinical Trial
Official title:
Impact of Intraoperative Dexmedetomidine on Long-term Outcomes in Elderly Patients After Major Non-cardiac Surgery: 3-year Follow-up of a Randomised Controlled Trial
Verified date | April 2022 |
Source | Peking University First Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a 3-year follow-up of patients enrolled in a previous randomized controlled trial which showed that intraoperative dexmedetomidine reduced delirium in elderly patients after major non-cardiac surgery. The purpose of this study is to clarify the effects of intraoperative dexmedetomidine on long-term outcomes of these patients.
Status | Completed |
Enrollment | 619 |
Est. completion date | April 1, 2021 |
Est. primary completion date | April 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Elderly patients (age =60 years); - Scheduled to undergo elective major non-cardiac surgery with expected duration =2 hours under general anaesthesia. Exclusion Criteria: - Do not provide written informed consent; - Previous history of schizophrenia, epilepsy or Parkinson's disease; - Visual, hearing, language or other barriers which impede communication and preoperative delirium assessment; - History of traumatic brain injury; - Severe bradycardia (heart rate <40 beats per minutes), sick sinus syndrome, or atrioventricular block of degree 2 or above without pacemaker; - Severe hepatic dysfunction (Child-Pugh grade C); - Renal failure (requirement of renal replacement therapy); - Neurosurgery. |
Country | Name | City | State |
---|---|---|---|
China | Peking University First Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University First Hospital |
China,
Abdel-Meguid ME. Dexmedetomidine as anesthetic adjunct for fast tracking and pain control in off-pump coronary artery bypass. Saudi J Anaesth. 2013 Jan;7(1):6-8. doi: 10.4103/1658-354X.109557. — View Citation
Cata JP, Singh V, Lee BM, Villarreal J, Mehran JR, Yu J, Gottumukkala V, Lavon H, Ben-Eliyahu S. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep;33(3):317-323. doi: 10.4103/joacp.JOACP_299_16. — View Citation
Gerresheim G, Schwemmer U. [Dexmedetomidine]. Anaesthesist. 2013 Aug;62(8):661-74. doi: 10.1007/s00101-013-2206-6. Review. German. — View Citation
Jalonen J, Hynynen M, Kuitunen A, Heikkilä H, Perttilä J, Salmenperä M, Valtonen M, Aantaa R, Kallio A. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology. 1997 Feb;86(2):331-45. — View Citation
Li Y, Wang B, Zhang LL, He SF, Hu XW, Wong GT, Zhang Y. Dexmedetomidine Combined with General Anesthesia Provides Similar Intraoperative Stress Response Reduction When Compared with a Combined General and Epidural Anesthetic Technique. Anesth Analg. 2016 Apr;122(4):1202-10. doi: 10.1213/ANE.0000000000001165. — View Citation
Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16. — View Citation
Wang BJ, Li CJ, Hu J, Li HJ, Guo C, Wang ZH, Zhang QC, Mu DL, Wang DX. Impact of dexmedetomidine infusion during general anaesthesia on incidence of postoperative delirium in elderly patients after major non-cardiac surgery: study protocol of a randomised, double-blinded and placebo-controlled trial. BMJ Open. 2018 Apr 21;8(4):e019549. doi: 10.1136/bmjopen-2017-019549. — View Citation
Zhang DF, Su X, Meng ZT, Li HL, Wang DX, Xue-Ying Li, Maze M, Ma D. Impact of Dexmedetomidine on Long-term Outcomes After Noncardiac Surgery in Elderly: 3-Year Follow-up of a Randomized Controlled Trial. Ann Surg. 2019 Aug;270(2):356-363. doi: 10.1097/SLA.0000000000002801. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival within 3 years after surgery | Overall survival within 3 years after surgery | Up to 3 years after surgery. | |
Secondary | Recurrence-free survival within 3 years after surgery. | Recurrence-free survival within 3 years after surgery. | Up to 3 years after surgery. | |
Secondary | Cancer-specific survival within 3 years after surgery. | Cancer-specific survival within 3 years after surgery. | Up to 3 years after surgery. | |
Secondary | Rate of new-onset disease or hospital readmission within 3 years after surgery. | Rate of new-onset disease or hospital readmission within 3 years after surgery. | Up to 3 years after surgery. | |
Secondary | Quality of life in 3-year survivors. | Quality of life is assessed with the World Health Organization Quality of Life-Brief Version. It assesses the quality of life at 4 domains, i.e., physical, psychological, social relationships, and environment. The score of each domain ranges from 0 to 100, with higher score indicating better quality of life. | At 3 years after surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04025840 -
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
|
Phase 4 | |
Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
Recruiting |
NCT03910140 -
TILA-TACE in Treatment of Hepatocellular Carcinoma
|
N/A | |
Completed |
NCT03923400 -
Jejunoileal vs Gastric GIST in the Era of Imatinib.
|
||
Withdrawn |
NCT02201381 -
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
|
Phase 3 | |
Recruiting |
NCT05392257 -
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
|
Phase 2 | |
Recruiting |
NCT05310357 -
Chromosomal Instability in Ovarian Cancer
|
||
Recruiting |
NCT05310370 -
HRD and Resistance to PAPPi in EOC Patients
|
||
Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
Active, not recruiting |
NCT04245644 -
Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
|
||
Recruiting |
NCT04245410 -
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
|
||
Completed |
NCT02980185 -
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT03967457 -
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
|
||
Recruiting |
NCT04050787 -
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
|
N/A | |
Recruiting |
NCT03892577 -
Real-world Study for Patients With Advanced Hepatobiliary Tumors
|
||
Completed |
NCT03726021 -
Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02942238 -
Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)
|
N/A | |
Not yet recruiting |
NCT01236989 -
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC
|
N/A | |
Recruiting |
NCT05218629 -
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
|
Phase 2 |